High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: Evidence for serum factors interfering with the binding to gp130

Clinical and Experimental Immunology

Volumn 131, Issue 2, 2003, Pages 355-363

  Pignatti, P ^a,d   Ciapponi, L ^b   Galle, P ^f   Hansen, M B ^f,g   Massa, M ^a   Meazza, C ^a   Paonessa, G ^b   Novick, D ^h   Ciliberto, G ^b   Martini, Alberto ^a,c   De Benedetti, F ^e  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IRBM   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d IRCCS   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f Rigshospitalet   (Denmark)

^g GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^h WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

gp130; IL 6 slL 6R complex; Interleukin 6

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ARTHRITIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATOMA CELL; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; IMMUNOPRECIPITATION; JUVENILE RHEUMATOID ARTHRITIS; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING;

ADOLESCENT; ANTIGENS, CD; ARTHRITIS, JUVENILE RHEUMATOID; AUTOANTIBODIES; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; BIOLOGICAL FACTORS; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; SOLUBILITY;

EID: 0037318484     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02052.x     Document Type: Article

References (48)

1. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1-78.
2. Hilbert DM, Kopf M, Mock BA, Köhler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasm. J Exp Med 1995; 182:243-8.
3. Hallek M, Leif Bergsagel P, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91:3-21.
4. Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interelukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74:1360-7.
5. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95:56-61.
6. Poli V, Balena R, Fattori E et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994; 13:1189-96.
7. Alonzi T, Fattori E, Lazzaro D et al. Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187:461-8.
8. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol, 1998; 28:2178-87.
9. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer gp130. Cell 1989; 58:573-81.
10. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-54.
11. Peters M, Jacobs S, Ehlers M et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996; 183:1399-406.
12. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994; 300:281-90.
13. Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993; 90:11924-8.
14. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995; 34:321-5.
15. Tajima S, Tsuji K, Ebihara Y et al. Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells. J Exp Med 1996; 184:1357-64.
16. Romano M, Sironi M, Toniatti C et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-25.
17. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999; 163:4583-9.
18. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble IL-6 receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93:2114-9.
19. Martini A, De Benedetti F. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998; 25:203-7.
20. May LT, Viguet H, Kenney JS, Ida N, Allison AC, Sehgal PB. High levels of 'complexed' interleukin-6 in human blood. J Biol Chem 1992; 267:19698-704.
21. May LT, Patel K, Garcia D, Ndubuisi MI, Ferrone S, Mittelman A, Mackiewicz A, Sehgal PB. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood 1994; 84:1887-95.
22. Ndubuisi MI, Patel K, Rayanade RJ, Mittelman A, May LT, Sehgal PB. Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J Immunol 1998; 160:494-501.
23. Jostock T, Mullberg J, Ozbek S et al. Soluble gp130 is a natural inhibitor of soluble interleukin-6 receptor transsignalling response. Eur J Biochem 2001; 268:160-7.
24. Narazaki M, Yasukawa K, Saito T et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82:1120-6.
25. Jostock T, Mullberg J, Ozbek S et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transignalling responses. Eur J Biochem 2001; 268:160-7.
26. Hansen MB, Svenson M, Abell K, Yasukawa K, Diamant M, Bendtzen K. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 1995; 25:348-54.
27. Takemura H, Suzuki H, Yoshizaki K, Ogata A, Yuhara T, Akama T, Yamane K, Kashiwagi H. Anti-interleukin-6 autoantibodies in rheumatic diseases. Arthritis Rheum 1992; 35:940-3.
28. Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis. Durban 1997. J Rheumatol 1998; 25:1991-4.
29. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin 6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34:1158-63.
30. Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76:2599-605.
31. Gregory B, Savino R, Ciliberto G. A fast and sensitive colorimetric assay for IL-6 in hepatoma cells based on the production of a secreted form of alkaline phosphatase (SEAP). J Immunol Meth 1994; 170:47-56.
32. Paonessa G, Graziani R, De Serio A et al. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signaling. EMBO J 1995; 14:1942-51.
33. Novick D, Engelmann H, Revel M, Leitner O, Rubinstein M. Monoclonal antibodies to the soluble human IL-6 receptor, affinity purification, ELISA, and inhibition of ligand binding. Hybridoma 1991; 10:137-46.
34. Savino R, Ciapponi L, Lahm A et al. Rational design of receptor super-antagonist of human interleukin-6. EMBO J 1994; 13:5863-70.
35. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998; 10:729-34.
36. Ledur A, Fitting C, David B, Hamberger C, Cavaillon JM. Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J Immunol Meth 1995; 186:171-9.
37. Krakauer T. Variability in the sensitivity of nine enzyme-linked immunosorbant assays (ELISAs) in the measurement of human interleukin 6. J Immunol Meth 1998; 219:161-7.
38. Tanaka M, Kishimura M, Ozaki S, Osakada F, Hashimoto H, Okubo M, Murakami M, Nakao K. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J Clin Invest 2000; 106:137-44.
39. Pepys MB, Booth SE, Tennent GA, Butler PJG, Williams DG. Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994; 97:152-7.
40. Du Clos TW, Marnell L, Zlock LR, Burlingame RW. Analysis of the binding of C-reactive protein to chromatin subunits. J Immunol 1991; 146:1220-5.
41. Suzuki H, Takemura H, Yoshizaki K et al. IL-6-anti-IL6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol 1994; 152:935-42.
42. Sporeno E, Paonessa G, Salvati AL, Graziani R, Delmastro P, Giliberto G, Toniatti C. Oncostatin M binds directly to gp130 and behaves as an interleukin-6 antagonist on a cell line expressing gp30 but lacking functional oncostatin M receptors. J Biol Chem 1994; 269:10991-5.
43. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and Oncostatin-M in rheumatoid arthritis. Arthritis Rheum 1997; 40:1096-105.
44. De Benedetti F, Pignatti P, Gerloni V et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997; 24:1403-9.
45. Bihl MP, Ruediger J J, Leufgen H, Hermann MJ, Perruchoud AP, Roth M, Tamm M. IL-6, potential new function and regulation through alternative splicing. Eur Respir J 2001; 18 (Suppl.):476s.
46. Atreya R, Mudter J, Finotto S et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583-8.
47. Lu YZ, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995; 86:3123-7.
48. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. Reshaping a human antibody to inhibit the interleukin 6 dependent tumor cell growth. Cancer Res 1993; 53:851-8.